BioSpace News Archive

NewAmsterdam Pharma Company N.V. announced the commencement of an underwritten public offering of 10,579,210 of the Company’s ordinary shares, with a nominal value of €0.12 per share, by certain of the Company’s existing shareholders affiliated with Forbion Capital Partners.

Vaxart, Inc. announced that it has commenced an underwritten public offering of its common stock.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced that it has commenced an underwritten public offering of $125 million of shares of its common stock.

Ionis Pharmaceuticals, Inc. announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Vivos Therapeutics, Inc. announced it plans to release its first quarter 2023 financial results after market close on Thursday, June 8, 2023.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today announced that management will be participating in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. PT.

Pasithea Therapeutics Corp. confirmed it has received an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a new indication for CARVYKTI®.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”) announced that management will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 12 – 15, 2023, in Dana Point, California.

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) is pleased to announce that it has increased the size of its previously announced non-brokered private placement (“Offering”) from up to $2 million in proceeds to $2,766,375 and 11,065,500 units (the “Units” or each a “Unit”).